Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, F.
Right arrow Articles by Kahn, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, F.
Right arrow Articles by Kahn, S. E.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:2514-2520, 2001
© 2001 by the American Diabetes Association, Inc.

Islet Amyloid Develops Diffusely Throughout the Pancreas Before Becoming Severe and Replacing Endocrine Cells

Feng Wang, Rebecca L. Hull, Josep Vidal, Miriam Cnop, and Steven E. Kahn

Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington

Islet amyloid occurs in >90% of type 2 diabetic patients and may play a role in the pathogenesis of this disease. To determine whether islet amyloid occurs diffusely throughout the pancreas, whether it affects islets equally, and whether it decreases islet endocrine cells, we characterized islet amyloidosis by computerized fluorescence microscopy in transgenic mice that develop typical islet amyloid. These mice produce the unique amyloidogenic component of human islet amyloid, human islet amyloid polypeptide (hIAPP). The prevalence of amyloid (number of islets containing amyloid/total number of islets x 100) and the severity of amyloid ({Sigma}amyloid area/{Sigma}islet area x 100) were found to be uniform throughout the pancreas. Furthermore, a high prevalence of amyloid was observed in islets when the severity of amyloid was only 1.5% of the islet area, suggesting a diffuse distribution of amyloid from the very early stages of islet amyloidosis. In 12 hIAPP transgenic mice with an amyloid severity of 9.6 ± 3.4%, the proportion of islets composed of ß- and {delta}-cells was reduced in the transgenic mice compared with 6 nontransgenic mice that do not develop amyloid (ß-cells: 62.9 ± 3.1% vs. 75.5 ± 0.9%, P = 0.02; {delta}-cells: 2.8 ± 0.5% vs. 4.4 ± 0.4%, P = 0.05), whereas the proportion of islets composed of {alpha}-cells did not significantly differ between the two groups of mice. In the individual islets in these transgenic mice, amyloid severity was inversely correlated with ß-cell, (r = -0.59, P < 0.0001), {alpha}-cell (r = -0.32, P < 0.0001), and {delta}-cell (r = -0.25, P < 0.0001) areas. In conclusion, islet amyloidosis occurs uniformly throughout the pancreas, affecting all islets before becoming severe. A reduction in islet endocrine mass starts at this early stage of islet amyloid development and progresses as amyloid mass increases.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Biophys. JHome page
C.-C. Lee, A. Nayak, A. Sethuraman, G. Belfort, and G. J. McRae
A Three-Stage Kinetic Model of Amyloid Fibrillation
Biophys. J., May 15, 2007; 92(10): 3448 - 3458.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Zraika, R. L. Hull, J. Udayasankar, A. Clark, K. M. Utzschneider, J. Tong, F. Gerchman, and S. E. Kahn
Identification of the Amyloid-Degrading Enzyme Neprilysin in Mouse Islets and Potential Role in Islet Amyloidogenesis
Diabetes, February 1, 2007; 56(2): 304 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Protein Sci.Home page
J. A. Williamson and A. D. Miranker
Direct detection of transient {alpha}-helical states in islet amyloid polypeptide
Protein Sci., January 1, 2007; 16(1): 110 - 117.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. J. Meier, R. Kayed, C.-Y. Lin, T. Gurlo, L. Haataja, S. Jayasinghe, R. Langen, C. G. Glabe, and P. C. Butler
Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1317 - E1324.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. L. Hull, M. R. Watts, K. Kodama, Z.-p. Shen, K. M. Utzschneider, D. B. Carr, J. Vidal, and S. E. Kahn
Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice
Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E703 - E709.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. L. Hull, Z.-P. Shen, M. R. Watts, K. Kodama, D. B. Carr, K. M. Utzschneider, S. Zraika, F. Wang, and S. E. Kahn
Long-Term Treatment With Rosiglitazone and Metformin Reduces the Extent of, but Does Not Prevent, Islet Amyloid Deposition in Mice Expressing the Gene for Human Islet Amyloid Polypeptide
Diabetes, July 1, 2005; 54(7): 2235 - 2244.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn
Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. L. Hull, S. Andrikopoulos, C. B. Verchere, J. Vidal, F. Wang, M. Cnop, R. L. Prigeon, and S. E. Kahn
Increased Dietary Fat Promotes Islet Amyloid Formation and {beta}-Cell Secretory Dysfunction in a Transgenic Mouse Model of Islet Amyloid
Diabetes, February 1, 2003; 52(2): 372 - 379.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.